ClinicalTrials.gg
Active, not recruitingNCT03293173Bio-CHICUpdated Jun 21, 2024

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

A Phase 2 interventional study of R-CHOEP and DA-EPOCH-R in Lymphoma, Large B-Cell, Diffuse, sponsored by Nordic Lymphoma Group. Active, not recruiting at 16 sites in 4 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Nordic Lymphoma Group · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Lymphoma, Large B-Cell, Diffuse with a site in Denmark — 8 open to participants now, 17 under way, 8 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Denmark.

Planned enrollment
25th of 36
120 · median 213
Started
2017
with 3 others
Phase 2
10 of 44
none open now
Primary completion
2021-01
later than 0 of 16 live
Registered
17th of 44
by date
Lead sponsor
4 of 44
Nordic Lymphoma Group

Among the 44 studies in Lymphoma, Large B-Cell, Diffuse with a site in Denmark, this one is the 25th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2017, is one of 10 in phase 2, reaches primary completion later than 0 of the 16 other live ones, and was the 17th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

8 of the 44 studies in Lymphoma, Large B-Cell, Diffuse with a site in Denmark are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Lymphoma, Large B-Cell, Diffuse with a site in Denmark, or all of them as a file.
02

Study summary

This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).

Read the detailed description

For young clinically high-risk diffuse large B-cell lymphoma (DLBCL) patients the optimal therapy has not been established. Previous Nordic phase II studies, where dose-dense chemoimmunotherapy (R-CHOEP-14) with systemic CNS prophylaxis (HD-Mtx and HD-AraC) was given, demonstrated favorable outcome in comparison to historical controls. However, the patients with biological risk factors, such as translocation of bcl2 and myc oncogenes or and/or high BCL2 and MYC expression or deletion 17p and/or high P53 expression had significantly higher risk of death, as compared to patients without aberrations. The figures provide evidence for an unmet clinical need for the patients with biological risk factors, and underscore the importance of a clinical trial, where both biological and clinical risk factors play a role in the treatment planning.

In this trial treatment intensity varies according to presence or absence of biological risk factors. All patients receive a prephase medication consisting of prednisone and vincristine and two cycles of R-CHOP and high dose (HD) methotrexate. Subsequently, depending on the biological risk factors either four additional cycles of R-CHOEP (standard arm with no risk factors) or four dose adjusted R-EPOCH courses (experimental arm with risk factors) are given, followed by one course of high dose cytarabine (Ara-C) and R. R-CHOEP courses should be given with a two-week and R-EPOCH with a three-week interval.

03

Conditions studied

  • Lymphoma, Large B-Cell, Diffuse

Keywords

  • DLBCL
  • Chemoimmunotherapy
  • High risk
  • CNS prophylaxis
  • Biomarker-driven
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 64 years
  • confirmed CD20+ DLBCL based on revised WHO 2008 Lymphoma Classification. The following subgroups and variants can be included:

    • ALK-positive large B-cell lymphoma
    • Intravascular large B-cell lymphoma
    • T-cell rich B-cell lymphoma
    • Myc/BCL-2 double hit lymphoma
    • Follicular lymphomas grade 3b
    • DLBCL with previously undiagnosed concurrent small cell infiltration in bone marrow, lymph node, or extranodal site and lymphomas intermediate between DLBCL and Burkitt's lymphoma are allowed
    • Posttransplantation lymphoma (PTLD), discordant or transformed lymphoma are NOT allowed
  • Patients in at least stage II with age adjusted IPI score of 2 or 3:

    • Stage III /IV and elevated LDH
    • Stage III/IV and 2 - 3
    • Stage II and elevated LDH and WHO performance status 2 - 3
  • And/or patients with site specific risk factors for CNS recurrence defined as follows

    • More than one extranodal site
    • Testicular lymphoma, stage IIE and higher
    • Paranasal sinus and orbital lymphoma with destruction of bone
    • Large cell lymphoma infiltration of the bone marrow
  • Previously untreated, except allowed
  • WHO performance status 0-3
  • Written

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac disease: cardiac function grade 3-4, \<45%
  • Impaired bone marrow liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule ( \< 9 g/dL, ANC \< 1.5 × 109/L, count \< 75 × 109/L, \< 40 mL/min, /AST > 2.5 x , 1.5 x ULN, > 1.5)
  • Pregnancy/lactation
  • Men and women of not agreeing to use effective during treatment and for 18 months after completion of treatment (Effective contraception is combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), hormone-releasing IUD, bilateral tubal occlusion, vasectomised partner, or sexual abstinence
  • Patients with other severe medical problems, including active infections, cardiac or pulmonary disease, history of PML and with an expected short survival for non-lymphoma reasons
  • Known positivity
  • Active or chronic virus (HBV) infection (defined as positive HBsAg serology), or active virus (HCV) infection (defined by antibody serology testing). HBsAg, HBcAb, and HCVAb must be tested during screening. Patients who have protective titers of HBsAb along negative HBsAg after vaccination or prior but cured hepatitis B are eligible.
  • Vaccination with a within one month prior to randomization
  • Patients with a that has been treated but not with curative intent, unless the malignancy has been in remission without treatment for ≥ 5 years prior to enrollment
  • Earlier treatment containing anthracyclines
  • Psychiatric or mental disorder which make the patient unable to give an and/or adhere to the protocol
  • CNS disease as diagnosed by MRI or CSF cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed
  • Transformed lymphoma
  • Primary mediastinal B-cell lymphoma
  • Pleural or peritoneal fluid that cannot be drained safely
  • to the active substance or any of the other ingredients
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • Patients participating in other clinical studies, unless followed for survival
  • Lower urinary tract constriction, which cannot be treated adequately
  • Degenerative and toxic encephalopathy
  • Neuromuscular disease
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group A

    Biologically low risk group, R-CHOEP-14

    Combination Product: R-CHOEP

  • Experimental
    Group B

    Biologically high risk group, DA-EPOCH-R

    Combination Product: DA-EPOCH-R

Interventions

  • Combination productR-CHOEP

    rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone

  • Combination productDA-EPOCH-R

    dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab

06

What researchers measure

Primary outcomes

  1. Time to treatment failure (TTF) of the patients with biological risk factors

    Interval between the registration date and the date of documented progression or lack of response, first relapse, death for any reason or discontinuation/change of therapy because of toxicity, whichever occurs first. Otherwise, patients will be censored at the last date they were known to be alive. For patients not responding at any time point on study treatment, TTF is defined as one day.

    Time frame: At 3 years

Secondary outcomes

  1. Time to treatment failure (TTF) at 3 years from date of registration of all patients and the patients in the low risk group

    Interval between the registration date and the date of documented progression or lack of response, first relapse, death for any reason or discontinuation/change of therapy because of toxicity, whichever occurs first. Otherwise, patients will be censored at the last date they were known to be alive. For patients not responding at any time point on study treatment, TTF is defined as one day.

    Time frame: At 3 years

  2. Incidence of treatment-emergent adverse events (Safety and tolerability)

    Number of patients with treatment-related adverse events graded according to the NCI CTCAE v 4.03

    Time frame: During the treatment period at the end of each cycle (14 or 21 days) up to 6 months. In addition, severe late toxicities during follow-up at 6 months intervals through study completion, an average of 5.5 years.

  3. Clinical response rate of all patients and the patients with biological risk factors

    Number of patients with complete or partial response

    Time frame: At the end of treatment cycles 2 and 7. Each cycle is two (group A) or three weeks (group B)

  4. CNS relapse rate

    Number of patients with CNS progression

    Time frame: At 1,5 years

  5. Progression free survival rate (PFS) of all patients and the patients with biological risk factors

    Time frame: At 3 years

  6. Overall survival rate (OS) of all patients and the patients with biological risk factors

    Time frame: At 3 years

  7. Molecular correlates for survival

    Identification of genomic aberrations (for example mutations and translocations), gene expression profiles and protein expression from the tumor tissue and circulation that predict clinical course of the disease

    Time frame: At 3 years

07

Study locations

16 sites
  • Aarhus University Hospital
    Aarhus, Denmark
  • Dept of Haematology, Rigshospitalet
    Copenhagen, 2100, Denmark
  • Dept of Haematology, Herlev Hospital, Copenhagen
    Herlev, Denmark
  • Dept haematology, Odense University hospital
    Odense, 5000, Denmark
  • Dept of Haematology, Sjaellands University hospital, Roskilde
    Roskilde, 4000, Denmark
  • Helsinki University Hospital Cancer Centre
    Helsinki, 00029, Finland
  • Keski-Suomen keskussairaala
    Jyväskylä, 40620, Finland
  • Kuopio University Hospital
    Kuopio, 70029, Finland
  • TAYS
    Tampere, 33521, Finland
  • Turku University Hospital, Syöpäklinikka
    Turku, 20520, Finland
  • Dept. of Oncology, Helse Bergen HF Haukeland sykehus
    Bergen, 5021, Norway
  • Oslo University Hospital
    Oslo, Norway
  • Dept. of Haematology and Oncology, Helse Stavander HF sykehuset
    Stavanger, 4011, Norway
  • Dept. of Oncology, Universitetssykehuset i Nord-Norge HF
    Tromsø, 9038, Norway
  • Dept of Oncology, St. Olavs hospital HF
    Trondheim, 7006, Norway
  • Skåne University Hospital
    Lund, Sweden
08

References and documents

Publications

  • Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppa S, Liestol K, Smeland EB, Holte H. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leuk Lymphoma. 2015 Jun;56(6):1742-9. doi: 10.3109/10428194.2014.970550. Epub 2014 Nov 19. PubMed 25284491 ↗
  • Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J, Sundstrom C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fossa A, Ostenstad B, Lofvenberg E, Nordstrom M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17. PubMed 23247661 ↗

Individual participant data

Plan to share: Yes — individual deidentified participant data (including data dictionaries) will be shared

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 3 months and ending 5 years following article publication

Access criteria: Researchers who provide a methodologically sound proposal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jan 2021, 41 months.

Of 210 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's 41 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2017
First posted
Sep 26, 2017
StartActual
Aug 4, 2017
Primary completionActual
Jan 31, 2021
CompletionEst.
Dec 31, 2024
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03293173
Lead sponsor
Nordic Lymphoma Group
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Aug 4, 2017
Primary completion
Jan 31, 2021
Completion
Dec 31, 2024 (estimated)
Last update
Jun 21, 2024

Study contacts

Sirpa Leppa, prof
principal investigator · Helsinki University Hospital Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion